ML

Marci Lillis

Vice President, Intellectual Property at FibroGen

Marci Lillis has had extensive work experience in the field of intellectual property law. Marci started their career as an Intellectual Property Attorney at Cooley Godward LLP in 1992 and worked there until 2002. From 2002 to 2008, they worked as a Diagnostics Patent Counsel at Novartis Vaccines and Diagnostics, Inc. In 2008, they joined FibroGen, Inc. as a Senior Director of Intellectual Property & Senior Patent Counsel and held this position until 2014. Marci then became an Executive Director of Intellectual Property & Senior Patent Counsel at FibroGen, Inc. until 2018. Currently, they hold the position of Vice President of Intellectual Property at FibroGen, Inc.

Marci Lillis earned a Doctor of Law (JD) degree from the University of California, College of Law, San Francisco (formerly UC Hastings) from 1993 to 1996. Marci also holds a PhD in Chemistry from the University of Pennsylvania. Furthermore, they have obtained a certification as a Registered Agent from the US Patent & Trademark Office, although the specific month and year of obtaining this certification are not provided.

Location

Emeryville, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


FibroGen

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.


Industries

Employees

501-1,000

Links